End-of-life health care utilization (EOLHCU) in patients with recurrent, metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with immune checkpoint inhibitors (IO).

Cameron Chalker,Rafael Santana-Davila,Jenna M. Voutsinas,Vicky Wu,Victoria Hwang,Christina S. Baik,Brittany Barber,Neal D. Futran,Jeffrey J. Houlton,George E. Laramore,Sylvia Lee,J.J. Liao,Upendra Parvathaneni,Renato Martins,Keith D. Eaton,Cristina P. Rodriguez

End-of-life health care utilization (EOLHCU) in patients with recurrent, metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with immune checkpoint inhibitors (IO).

2020

Cameron Chalker
Rafael Santana-Davila
Jenna M. Voutsinas
Vicky Wu
Victoria Hwang
Christina S. Baik
Brittany Barber
Neal D. Futran
Jeffrey J. Houlton
George E. Laramore
Sylvia Lee
J.J. Liao
Upendra Parvathaneni
Renato Martins
Keith D. Eaton
Cristina P. Rodriguez

e18516Background: Demographic and EOLHCU trends are undefined in the growing population of IO-treated RMHNSCC; we sought to study these in a single institution retrospective study. Methods: We iden...

Keywords:

Oncology
in patient
Health care
Pathology
Internal medicine
immune checkpoint inhibitors
Head and neck squamous-cell carcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations